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Abstract
Background: Prostaglandins are important for female reproduction. Prostaglandin-E2 acts via four different
receptor subtypes, EP1, EP2, EP3 and EP4 whereas prostaglandin-F2alpha acts through FP. The functions of
prostaglandins depend on the expression of their receptors in different uterine cell types. Our aim was to
investigate the expression of EPs and FP in rat uterus and to identify the regulation by estradiol, progesterone and
estrogen receptor (ER) selective agonists.
Methods: We performed four different rat experiments involving treatments with estradiol, progesterone and ER
agonists. Real-time PCR and immunohistochemistry were employed to evaluate receptor expression.
Results: Our results showed that all mRNAs and proteins of EPs and FP are expressed in the rat uterus. The
expression pattern and intensity of immunostaining vary between different cell types and treatments. The mRNA
expression of all EPs and FP are downregulated by estradiol and the ERalpha specific agonist PPT, whereas the
ERbeta specific agonist DPN downregulates only EP2 and EP4. The protein expression however, showed an
increase in EP2 and EP3 after estradiol treatment. When treated with estradiol and progesterone in combination,
the expressions of EP1 and EP3 are upregulated.
Conclusions: Regulation of EPs and FP expression by estradiol appears to be mainly modulated via ERalpha for
EP1, EP3 and FP, while EP2 and EP4 also are affected by the ERbeta selective ligand. Our immunohistochemical
data shows a cell specific regulation of prostaglandin receptors under the influence of ovarian steroids, where EP2
is estrogen regulated in all uterine tissues examined. EP1 and EP3 are upregulated by the combination of estradiol
and progesterone. Thus, our observations indicate that estradiol and progesterone regulate the mRNA and protein
expression of EPs and FP in a receptor and tissue specific way.
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Background
Prostaglandins are inflammatory mediators that play an
important role in female reproduction [1-5]. Prostaglan-
din (PG) receptors are heptahelical transmembrane G
protein coupled receptors and are expressed in cytoplas-
mic membranes [6,7]. PGE2 transduces its signal
through four different receptor subtypes, EP1, EP2, EP3
and EP4 whereas the action of PGF2a is mediated by
FP [8,9]. These receptors have a distinct differential
affinity to ligands, biochemical properties and tissue
localization [8]. PGE2 and PGF2a are key factors in
female reproduction with vital functions in blastocyst
spacing, implantation, decidualization and uterine con-
traction [2,9]. EP1, EP3 and FP cause smooth muscle
contraction, whereas EP2 and EP4 contribute to the
relaxation of smooth muscles [8,10]. EP2, EP3 and EP4
might play a role in the regulation of stromal edema,
endometrial blood flow and blood vessel permeability
[1].
Key reproductive events are under the strict control of
estrogen and progesterone (P4). There are reports sug-
gesting that sex steroids can modulate the expression of
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temporal and cell-specific manner around the time of
embryo implantation and decidualization [2,3,11,12].
Further, P4 upregulates EP2 expression and estradiol
(E2) augments this process; however, E2 alone downre-
gulates EP2 [3]. In rats, EP2 mRNA levels are upregu-
lated during pregnancy and their levels decline during
labor and postpartum, suggesting a possible involvement
of P4 in the regulation of EP2. Moreover, P4 upregulates
EP2 mRNA in the uterus of ovariectomized rats [13]. A
recent study on human endometrium showed that the
expression of PG receptors varies throughout the men-
strual cycle in a phase specific manner with EP2, EP3
and EP4 dominating the mid-secretory phase, EP1 dom-
inating early-secretory phase and FP peaking during the
proliferative phase [1] indicating that E2 and P4 might
regulate their expression. Thus there are both direct and
indirect results indicating steroidal regulation of PG
receptors in different species. These results add to the
existing complexity of the regulation of the reproductive
cycle suggesting interplay between the sex steroid hor-
mone and PG systems.
We hypothesized that E2 and P4 might regulate the
spatio-temporal expression of PG receptors in the rat
uterus. E2 acts via its receptors, estrogen receptor (ER)
a and b. It is not known if both these receptors are
involved in the regulation of PG receptors. Further, it is
also not known if there is any dose or time dependent
regulation of PG receptors by E2 alone and in combina-
tion with P4. The aim of this study is to evaluate cell
specific expression of PG receptors EPs and FP in the
rat uterus and how they are regulated by E2, P4 and ER
selective agonists.
Methods
Reagents
Estradiol-17b and progesterone were purchased from
Sigma Chemical Co. St. Louis, MO, USA. The hormones
were dissolved in 99.5% ethanol at a high concentration
and then diluted with propylene glycol to the required
concentration. The final concentration of ethanol in the
injections was less than 5%. The ERa selective ligand
4,4’,4’’-(4-Propyl-[1H]-pyrazole-1,3,5-triyl)trisphenol
(PPT) and the ERb selective ligand 2,3-bis(4-Hydroxy-
phenyl)-propionitrile (DPN) were purchased from Tocris
Bioscience, Bristol, UK. RNAlater
® was purchased from
Ambion, Austin, TX, USA.
Animals
Adult female rats (55-60 days old, approx. 250 g) of the
Sprague-Dawley strain (BK-Universal, Sollentuna, Swe-
den) were used in all four experiments. The animals
were housed in a controlled environment at 20°C on an
illumination schedule of 12L: 12D. The rats had
unlimited access to standard pellet food and water. Rats
were ovariectomized and given two weeks to rest before
proceeding with the treatments. The studies were
approved by the committee on animal care in Sweden.
Study 1, Effect of estradiol dose
The ovariectomized rats (n = 22) were divided into four
groups. Three groups were treated with E2 subcuta-
neously at doses 1.0 μg( n=4 ) ,2 . 5μg( n=6 )o r5μg
(n = 6) per rat and day for two days. The control group
(n = 6) was treated with vehicle alone.
Study 2, Effect of time
The ovariectomized rats (n = 27) were divided into four
groups and treated subcutaneously with 2.5 μgo fE 2
daily for 1 day (n = 7), 4 days (n = 7) or 7 days (n = 6).
The control group (n = 7) received vehicle alone.
Study 3, Effect of estradiol and progesterone
Forty-two ovariectomized rats were divided into seven
groups (n = 6). They were treated by subcutaneous
injections with either vehicle, 2.5 μgo fE 2p e rr a ta n d
day, and/or 1 mg P4 per rat and day. They were treated
with E2 and/or P4 for 24 or 48 hours. The treatment
sequence is shown in Table 1.
Study 4, Mode of action of estradiol
Four groups of ovariectomized rats (n = 31) were trea-
ted with vehicle, E2, ERa selective or ERb selective ago-
nists, PPT or DPN, respectively. The animals were
subcutaneously administered either 5.0 μgo fE 2( n=8 )
or 1.25 mg of PPT (n = 8) or 3.125 mg of DPN (n = 7)
or vehicle (n = 8). The rats were killed 24 h after treat-
ment. The doses of PPT and DPN were chosen by com-
paring data on the activity of the agonists and were
prepared as reported earlier [14].
Tissue Collection
At sacrifice, the rat uterus was removed, stripped of fat
and connective tissue. In study 1 and 4 one portion was
stored in RNAlater
® for RNA preparation and another
Table 1 Treatment schedule of study 3
Groups Day 1 Day 2 Day 3
OvxC vehicle vehicle Sacrificed
24E E2 Sacrificed
24P P4 Sacrificed
48EE E2 E2 Sacrificed
48PP P4 P4 Sacrificed
48EP E2 P4 Sacrificed
48PE P4 E2 Sacrificed
OvxC (Ovariectomized controls), E2 (Estradiol 17-b, 2.5 μg/rat), P4
(Progesterone, 1 mg/rat)
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room temperature (RT) overnight and then stored in
70% ethanol in 4°C to be embedded for immunohisto-
chemistry. In study 2 and 3, tissues were only prepared
for immunohistochemistry.
RNA preparation and reverse transcription
Total RNA from uterine tissues were purified with
RNeasy
® Mini kit (Qiagen GmbH, Hilden, Germany)
according to the manufacturer’s protocol for fibrous tis-
sues. The protocol included an on-column DNase diges-
tion, as recommended by the manufacturer. Two
micrograms of total RNA from each sample was reverse
transcribed at 37°C for 60 min in a final volume of 20
μl with a reaction mixture (Qiagen) containing 1 × RT
buffer, dNTP mix (0.5 mM each dNTP), 600 ng random
primers (Invitrogen, Paisley, UK), 30 units RNase inhibi-
tor (Qiagen GmbH, Hilden, Germany), and 4 U of
Omniscript™ reverse transcriptase (Qiagen).
Real time PCR analysis
The oligonucleotide primers for EP1, EP2, EP3, EP4, FP
and Rplp0 (housekeeping gene) are presented in Table
2, along with their predicted sizes. Real time PCR was
p e r f o r m e di na ni C y c l e r ™ iQ Real Time PCR System
(Bio-Rad Laboratories, Inc, CA USA). For PCR, the
cDNAs corresponding to 50 ng RNA were added to
12.5 μlo fi Q ™ SYBR
® Green Supermix (Bio-Rad) and
0.3 μM of each oligonucleotide primer in a final volume
of 25 μl. After initial incubation for 3 min at 95°C, the
samples were subjected to 40 cycles of 10 s at 95°C, fol-
lowed by 45 seconds annealing at 57 to 64°C depending
upon the genes (Table 2). All PCR assays were per-
formed in duplicates. The purity of PCR products was
confirmed by a melting curve analysis in all experi-
ments. Each PCR assay included a negative control con-
taining an RNA sample without reverse transcription.
The primer pairs (Table 2) were designed with NCBI/
Primer-BLAST program.
Immunohistochemistry
Paraffin embedded blocks were cut in 5 μm thick sec-
tions and mounted on histological slides. The paraffin
sections were deparaffinized, rehydrated and washed
with phosphate-buffered saline (PBS; pH 7.4). Antigen
retrieval was performed by boiling the sections in 0.01
M sodium citrate buffer (pH 6.0) in microwave for 10
min. The endogenous peroxidase activity was quenched
by placing the slides in 3% hydrogen peroxide in metha-
nol. The slides were then blocked with 1.5% normal
donkey serum followed by incubation with primary anti-
bodies. Primary antibodies (Cayman Chemicals, Michi-
gan, USA) were incubated overnight at 4°C. The
antibodies were incubated by diluting to final concentra-
tions of 3 μg/ml for EP1 (Cat # 101740), 2 μg/ml for
EP2 (Cat # 101750), 1.5 μg/ml for EP3 (Cat # 101760),
10 μg/ml for EP4 (Cat # 101775) and 5 μg/ml for FP
(Cat # 101802). The specificities of the antibodies were
verified by performing western blot using rat uterine
extracts (data not shown). These antibodies have been
used and verified before in rat tissues [15,16]. The nega-
tive controls were obtained by replacing the primary
antibody with an equal amount of rabbit IgG. There-
after, incubation with biotin conjugated donkey anti-rab-
bit secondary antibody (SantaCruz, CA, USA) was
p e r f o r m e da tR Tf o r3 0m i na tad i l u t i o no f1 : 1 0 0 0 .
Further, incubation with avidin-biotin horseradish per-
oxidase complex was performed at RT for 30 min using
Vectastain elite
® ABC kit (Vector labs, CA USA). The
location where the enzyme was bound was visualized by
the addition of the substrate 3,3’-diaminobenzidine
(DAKO, CA, USA), a chromogen which produces a
brown insoluble precipitate. The sections were then
counterstained with haematoxylin, which was followed
by dehydration and mounting with Pertex. A Leica
microscope was used to evaluate the slides. The staining
intensities were assessed semi-quantitatively by manual
scoring. All the slides were evaluated for the five differ-
ent tissue compartments (luminal epithelia, glandular
Table 2 Oligonucleotide primers used for real-time PCR
Gene Accession No. Primers
F = forward; R = reverse
Product Size Annealing Temp.
EP1 NM_013100.1 F: 5’-AGCCCCCTGCTGGTATTGGT-3’
R: 5’-AGGATCTGGTTCCACGACGCGA-3’
107 63
EP2 NM_031088.1 F: 5’-GCTCCCTGCCTTTCACAATCTTTGC-3’
R: 5’-TGGAGCTTCCGGTGCTCTCAGT-3’
200 60
EP3 NM_012704.1 F: 5’-ACTGTCCGTCTGCTGGTCGC-3’
R: 5’-TGGTTCAGCGAAGCCAGGCG-3’
147 64
EP4 NM_032076.3 F: 5’-ATTCCGCTCGTGGTGCGAGTGT-3’
R: 5’-CACCAATGCGGCAGAAGAGGCA-3’
202 60
FP NM_013115.1 F: 5’-TCAGCAGCACAGGCAAGGCA-3’
R: 5’-TGGCCATCGTCACCAGAAAGGGA-3’
110 64
Rplp0 NM_001002.3 F: 5’-GGCGACCTGGAAGTCCAACT-3’
R: 5’-CCATCAGCACCACAGCCTTC-3’
149 57
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ing was performed independently by two investigators
blinded to the identity of the slides. The staining inten-
sity was arbitrarily graded on a scale of (0) no staining,
(1) faint, (2) moderate and (3) strong.
Statistics
Statistical analyses for all studies were carried out by
Kruskal-Wallis test (ANOVA on ranks) and the signifi-
cances were evaluated by Dunn’st e s tu s i n gS i g m ap l o t
®
software. Values are considered significant when P < 0.05.
Results
Study 1, Regulation of EP and FP receptors by different
doses of estradiol
Real-time PCR data showed that E2 downregulates the
expression of EPs and FP mRNAs in the uterus (Figure
1). The decrease was significant (p < 0.05) for EP1 and
EP4 at low dose treatment (1.0 μg ) ;E P 2 ,E P 3a n dF Pa t
mid dose (2.5 μg) and for the expression of all receptors
when treated with the highest dose (5.0 μg). However,
results from immunohistochemistry showed that there is
an increase in the immunostaining of EP2 and EP3 fol-
lowing E2 treatments (Figure 2 and 3). There is an
increase (p < 0.05) in the immunostaining of EP2 when
treated with 5.0 μg of E2 in luminal epithelium, glandu-
lar epithelium, stroma and myometrium when compared
to controls. In blood vessels a similar tendency was
seen. EP3 immunostaining was increased (p < 0.05) in
stroma and myometrium when treated with 2.5 μgo fE 2
(Figure 3). Corresponding tendencies could be observed
in stroma and myometrium of study 3 after a compar-
able E2 treatment. Luminal epithelium, glandular epithe-
lium and blood vessels also show similar trends.
Immunostaining of the EP1, EP4 and FP receptors did
not show any significant differences (data not shown).
Study 2, Time dependent upregulation of EP2 receptor
proteins by estradiol
Immunohistochemical scores showed a time depended
upregulation of EP2 in rat uteri when treated with 2.5
μg of E2 (Study 2). An increase (p < 0.05) in immunos-
taining could be observed in myometrium from day 1
but in luminal epithelium, glandular epithelium and
stroma the increase was significant after day 4 (Figure
4). The increase (p < 0.05) was significant in all the cell
types including the blood vessels after 7 days of treat-
ment with E2. Our observations from studies 1 and 3
show that EP2 is not upregulated after treatment with
2.5 μg of E2 for 2 days (Figure 3) or 1 day respectively,
except for myometrium on day 1 (Figure 5). The myo-
metrial EP2 expression showed similar upregulation
after day 1 in both study 2 (Figure 4) and study 3 (Fig-
ure 5) where a similar dose of E2 was used. The other
PG receptors examined did not show significant regula-
tion after E2 treatment (data not shown).
Study 3, Regulation of EP and FP receptors by combined
estradiol and progesterone treatment
In general, it was observed that there is a strong ten-
dency for increased immunostaining of EP1 in all the
compartments when treated together with E2 and P4,
irrespective of the sequence of the treatments (Figure 5).
In stroma we could observe an increase in immunos-
taining (p < 0.05) when treated with E2 followed by P4,
when compared to vehicle treated control or E2 alone.
Further, in myometrium an increase in immunostaining
(p < 0.05) could be observed between the controls and
groups treated with E2 and P4 irrespective of the treat-
ment sequence. EP3 expression was upregulated (p <
0.05) when treated with P4 after priming with E2 in
Figure 1 Regulation of EP and FP mRNA by estradiol.T h e
relative mRNA expression levels of EP1, EP2, EP3, EP4 and FP as
measured by real-time PCR in uteri from ovariectomized rats treated
with different doses of estradiol (E2) along with vehicle treated
controls (OvxC). Box and whisker plots representing the median
value with 50% of all data falling within the box. The whiskers
extend to the 5th and 95th percentiles. Bars with asterisks are
significantly (P < 0.05) different from OvxC.
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5). Luminal epithelium and blood vessels showed similar
tendencies although not statistically significant (data not
shown). EP2 was upregulated (p < 0.05) in myometrium
when treated with E2 alone after 24 h (Figure 5) but
there was no change in the other cell types in any of the
combined treatments. Treatment with P4 alone did not
affect the regulation of any of the PG receptors
investigated in this study. EP4 and FP did not show any
regulation when treated with E2 or P4 alone or in
combination.
Study 4, Estradiol and ER selective agonists regulate the
expression of EPs and FP receptor
Our results from real-time PCR analyses show that 5.0
μgo fE 2a n dt h eE R a a g o n i s tP P Td o w n r e g u l a t e d( p<
Figure 2 Localization of EP and FP protein and their regulation by estradiol. Immunohistochemical localization of prostaglandin receptors
in luminal epithelium (LE), glandular epithelium (GE), stroma (Str), myometrium (M) and blood vessels (arrows) in the uteri of ovariectomized
controls and different doses of estradiol (E2) treated rats. Representative images of EP2 (A-D); OvxC (A), treatment with 1 μg E2 (B), 2.5 μg E2 (C)
and 5 μg E2 (D), EP3 (E-H); OvxC (E), treatment with 1 μg E2 (F), 2.5 μg E2 (G) and 5 μg E2 (H). Representative images of EP1 (I), EP4 (J), FP (K)
immunostaining and a negative control (L). Magnification - 200X, Scale bar = 100 μm.
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Treatment with the ERb agonist DPN resulted in a
downregulation (p < 0.05) of EP2 and EP4 mRNA
expressions (Figure 6). However, immunohistochemical
scores showed an upregulation (p < 0.05) of the EP2
and EP4 proteins in stroma when treated with E2 (data
not shown).
A summary of immunohistochemical results of the
significantly regulated receptors from all the four studies
are given in table 3.
Discussion
Our study shows that EPs and FP are localized in differ-
ent cell types of the rat uterus suggesting their
Figure 3 Regulation of EP2 and EP3 protein by different doses of estradiol. Results from manual scoring of EP2 and EP3 immunostaining
in different uterine cell types when treated with different doses of estradiol (E2). Box and whisker plots representing the median value with 50%
of all data falling within the box. The whiskers extend to the 5th and 95th percentiles. Bars with asterisks are significantly (P < 0.05) different
from the control group (OvxC). LE- luminal epithelium, GE- glandular epithelium.
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receptors are G protein coupled receptors, they are also
localized to cytoplasm and nucleus [5,7,10,17,18]. We
observed EPs and FP in cytoplasm and membranes,
although some nuclear staining was seen in EP1 and
EP4. Nuclear PG receptors have been reported to per-
form intracrine signaling by activating transcription
[18,19].
The mRNA data shows that EPs and FPs are regulated
by E2. It has been reported that P4 does not regulate
mRNA of EPs, but upregulated EP2, EP3 and EP4 pro-
teins in rat cervix [20]. In the uterus of ovariectomized
rodents EP2 mRNA increased when given P4 alone or
co-treated with E2 [3,13]. We did not have mRNA data
to compare, but upregulation of EP2 protein levels by
P4 was not found in our study. EP2 mRNA expression
was downregulated by E2 in mice [3] which is in agree-
ment with our observation in rats. Previous studies have
shown the regulation of EP2, EP3 and EP4 mRNAs by
E2 in pseudopregnant endometrium [21] and EP2, EP3
and EP4 protein by P4 in rat cervix [20] showing steroi-
dal regulation of EPs. However, most conclusions in
previous studies on mice are based only on RNA levels
[2,3,11,13,21] and few studies shows the regulation of
protein levels [5,12]. We showed that the ERa selective
agonist PPT downregulates all EPs and FP mRNAs,
whereas the ERb agonist DPN downregulates EP2 and
EP4 mRNAs. We did not observe any differences in pro-
tein expression after PPT or DPN treatment. This could
be due to the short duration of the treatments. These
observations indicate that ERa may play a major role in
the regulation of EPs and FP mRNA expression. It is
known that ERa is the dominant ER subtype in rat
uterus [22]. The expression of EP2 and EP4 are
decreased also by DPN in addition to E2 and PPT.
Thus, ERb could be involved in relaxation of the uterine
smooth muscle cells. The mRNA level of FP was
decreased by E2 and PPT, but not DPN treatment, indi-
cating an ERa mediated FP regulation. None of the PG
receptors inducing contraction are affected by DPN.
Our study shows the expression of EPs and FP pro-
teins are differentially regulated by ovarian steroids.
Interestingly, EP2 and EP4 proteins are exclusively regu-
lated by E2 but EP1 and EP3 proteins are regulated only
by a combination of E2 and P4. FP protein levels appear
to be insensitive to ovarian steroids. Thus, the contrac-
tion mediating receptors are regulated exclusively by a
combination of E2 and P4, while the relaxatory recep-
tors are regulated only by E2. EP2 regulates epithelial
differentiation and implantation [3,12,23]. E2 is known
to induce proliferation and changes in epithelium in
preparation for implantation [24]. Thus, regulation of
EP2 by E2 in epithelium may be important for implanta-
tion. Further, EP2, EP3 and EP4 are known to play vital
roles in decidualization [21]. Our findings show that
administration of P4 after E2p r i m i n gu p r e g u l a t e sE P 1
and EP3, indicating the role of both steroids in the regu-
lation of EPs in stroma during decidualization. These
receptors may be regulated via a P4 mediated pathway
[20]. EP4, upregulated in stroma by E2 in our study, is
known to trigger decidualization under the direction of
ovarian steroids [21]. PG receptors can constrict (EP1
and EP3) or dilate (EP2) blood vessels [23,25,26]. Treat-
ment with E2 increased EP2 protein in blood vessels
indicating that uterine blood flow could be regulated by
E2 via EP2. It was recently reported that the expression
of EP2, EP3 and EP4 increased in human endometrium
during the mid-secretory phase, coinciding with
increased stromal edema, blood vessel permeability and
blood flow [1]. We could also show that E2 upregulates
Figure 4 Temporal regulation of EP2 protein by estradiol. Immunohistochemical localization of prostaglandin receptors in luminal
epithelium (LE), glandular epithelium (GE), stroma (Str), myometrium (M) and blood vessels (arrows) in the uterus of ovariectomized rats.
Representative images of EP2 (A-D); OvxC (A), treatment with estradiol (E2) for 1 day (B), 4 days (C) and 7 days (D). Magnification - 200X, Scale
bar = 100 μm.
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Interestingly, when treated with E2 in combination with
P4, there is an upregulation of EP1 and EP3 also in myo-
metrium. It appears that E2 and P4 act synergistically to
increase the expression of EP1 and EP3 and estrogen
priming seems to be especially important for EP3. Thus,
EPs may modulate the contractile and relaxatory func-
tions under the regulation of steroid hormones.
E2 downregulates the mRNA levels of EPs and FP, but
their protein levels were either upregulated or
unchanged suggesting a multilayered regulation of RNA
and protein. This apparent discrepancy has to be inter-
preted with caution. It is not possible to compare
mRNA results with protein, as RNA data shows the
total expression while immunohistochemistry detects
the protein in a cross section. However, it is interesting
to note that such discrepancies have been reported
before [1,12,20,27]. Although there are justifications
based on the techniques used, we speculate that there
may be a post-transcriptional regulation. Estrogen is
known to regulate mRNA stability of many genes [28],
and could be the possible regulator. A weakness of the
present study is that only RNA data from studies 1 and
4 are analyzed. It would have added strength to the
study if RNA levels from studies 2 and 3 had been avail-
able, enabling studies of long duration of E2 treatment
and E2 and P4 combined effects.
The exact mechanisms of the steroidal regulation of
PG receptors at transcription and translation are not
clear. There are reports showing the presence of
response elements in PG receptor genes that could be
utilized by E2 and P4 to regulate their expression. EP1
Figure 5 Cell type specific regulation of EP1, EP2 and EP3 by estradiol and progesterone. Results from manual scoring of EP1 (stroma and
myometrium), EP2 (myometrium) and EP3 (glandular epithelium (GE), stroma and myometrium) when treated with estradiol (E), progesterone (P),
or combinations for 24 (E or P) and 48 hours (EE, PP, EP or PE). Box and whisker plots representing the median value with 50% of all data falling
within the box. The whiskers extend to the 5th and 95th percentiles. Values with different letter designations are significantly different (P < 0.05).
Blesson et al. Reproductive Biology and Endocrinology 2012, 10:3
http://www.rbej.com/content/10/1/3
Page 8 of 10has an estrogen response element and AP1 element
[29,30], EP2 has a progesterone receptor binding ele-
ment [31], EP3 and EP4 have SP1 binding sites and the
FP promoter contains AP1 and SP1 sites [32,33]. Thus,
it is possible that E2 and P4 directly or indirectly regu-
late the expression of PG receptors through these
binding sites. E2 can also bind to G-protein coupled
estrogen receptor-1 (GPER) to activate kinase mediated
pathways [34] which may also regulate the expression of
PG receptors.
Conclusions
O u rs t u d ys h o w st h a tE P sa n dF Pm R N A sa n dp r o t e i n s
are regulated by E2 and P4. E2 appear to modulate the
regulation of EP1, EP3 and FP via ERa, while EP2 and
EP4 could also be regulated via ERb. Immunohisto-
chemical data shows a cell specific regulation of PG
receptors under the influence of ovarian steroids. EP2 is
estrogen regulated in all uterine cell types examined
whereas EP1 and EP3 are upregulated by the combina-
tion of E2 and P4 in stroma and myometrium. Further
investigations are required to dissect the exact molecular
mechanism by which steroid hormones regulate the
expressions of PG receptors.
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2.5 μg E2 4 and
7 days)
Increased
(5 μg E2 24 h and 48 h, 2.5 μg
E2 4 and 7 days)
Increased
(5 μg E2 48 h, 2.5 μgE 21 ,4
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